SEC Comment Letter for BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063) — Feb 26, 2020
BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)
Date: Feb. 26, 2020 · CIK: 0001580063 · Accession: 0000000000-20-001750
AI Filing Summary & Sentiment
Letter
February 26, 2020 Harry Stylli, Ph.D. Chief Executive Officer Progenity, Inc 4330 LaJolla Village Drive, Suite 200 San Diego, CA 92122 Re:Progenity, Inc. Draft Registration Statement on Form S-1/A Amended on February 14, 2020 CIK No. 0001580063 Dear Dr. Stylli: We have reviewed your amended draft registration statement and have the following comment. Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing the information you provide in response to this comment and your amended draft registration statement or filed registration statement, we may have additional comments. Draft Registration Statement on Form S-1, amended on February 14, 2020 New Product Development, page 84 1.We note your response to prior comment nine, and the revision made at page 84 of your amended filing. Please revise to identify which components of the regulatory approval pathway constitute, or may constitute, key development milestones for your product candidates. You may contact Eric Atallah, Staff Accountant, at 202-551-3663, or Lisa Vanjoske, Staff Accountant, at 202-551-3614, if you have questions regarding comments on the financial statements and related matters. Please contact Paul Fischer, Staff Attorney, at 202-551-3415, or Celeste M. Murphy, Legal Branch Chief, at 202-551-3257, with any other questions.
FirstName LastNameHarry Stylli, Ph.D. Comapany NameProgenity, Inc February 26, 2020 Page 2 FirstName LastName Harry Stylli, Ph.D. Progenity, Inc February 26, 2020 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences cc: Branden C. Berns, Esq.
Show Raw Text
February 26, 2020
Harry Stylli, Ph.D.
Chief Executive Officer
Progenity, Inc
4330 LaJolla Village Drive, Suite 200
San Diego, CA 92122
Re:Progenity, Inc.
Draft Registration Statement on Form S-1/A
Amended on February 14, 2020
CIK No. 0001580063
Dear Dr. Stylli:
We have reviewed your amended draft registration statement and have the following
comment. Please respond to this letter by providing the requested information and either
submitting an amended draft registration statement or publicly filing your registration statement
on EDGAR. If you do not believe our comment applies to your facts and circumstances or do
not believe an amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to this comment and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Draft Registration Statement on Form S-1, amended on February 14, 2020
New Product Development, page 84
1.We note your response to prior comment nine, and the revision made at page 84 of your
amended filing. Please revise to identify which components of the regulatory approval
pathway constitute, or may constitute, key development milestones for your product
candidates.
You may contact Eric Atallah, Staff Accountant, at 202-551-3663, or Lisa Vanjoske,
Staff Accountant, at 202-551-3614, if you have questions regarding comments on the financial
statements and related matters. Please contact Paul Fischer, Staff Attorney, at 202-551-3415, or
Celeste M. Murphy, Legal Branch Chief, at 202-551-3257, with any other questions.
FirstName LastNameHarry Stylli, Ph.D.
Comapany NameProgenity, Inc
February 26, 2020 Page 2
FirstName LastName
Harry Stylli, Ph.D.
Progenity, Inc
February 26, 2020
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Branden C. Berns, Esq.